Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis-Reference-Cited by-同舟云学术

Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis

Published:2022-06 Issue: Volume:62 Page:103737
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Satyanarayan Sammita,Safi Neha,Sorets Tali,Filomena Susan,Zhang Yinan,Klineova Sylvia,Fabian Michelle,Horng Sam,Tankou Stephanie,Miller Aaron,Krieger Stephen,Lublin Fred,Sumowski James,Katz Sand Ilana

Funder

Greenwich Biosciences

Biogen

MedDay Pharmaceuticals

Teva Pharmaceutical Industries

National Institutes of Health

Novartis

TG Therapeutics

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference29 articles.

1. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies;Achiron;Ther. Adv. Neurol. Disord.,2021

2. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate;Addetia;J. Clin. Microbiol.,2020

3. A serological assay to detect SARS-CoV-2 seroconversion in humans;Amanat;Nat. Med.,2020

4. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults;Anderson;N. Engl. J. Med.,2020

5. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy;Apostolidis;Nat. Med.,2021

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study;Frontiers in Immunology;2024-08-19

2. De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate;Advances in Therapy;2024-06-11

3. Analysis of seroconversion following COVID-19 vaccination among multiple sclerosis patients treated with disease-modifying therapies in Poland;Neurologia i Neurochirurgia Polska;2024-02-29

4. Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination;Multiple Sclerosis Journal;2023-09-30

5. Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-Analysis Using GRADE;2023-08-13